Multifactorial Contribution of Notch Signaling in Head and Neck Squamous Cell Carcinoma by Porcheri, Cristina et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Multifactorial Contribution of Notch Signaling in Head and Neck Squamous
Cell Carcinoma
Porcheri, Cristina ; Meisel, Christian Thomas ; Mitsiadis, Thimios
Abstract: Head and neck squamous cell carcinoma (HNSCC) defines a group of solid tumors originating
from the mucosa of the upper aerodigestive tract, pharynx, larynx, mouth, and nasal cavity. It has
a metastatic evolution and poor prognosis and is the sixth most common cancer in the world, with
600,000 new cases reported every year. HNSCC heterogeneity and complexity is reflected in a multistep
progression, involving crosstalk between several molecular pathways. The Notch pathway is associated
with major events supporting cancerogenic evolution: cell proliferation, self-renewal, angiogenesis, and
preservation of a pro-oncogenic microenvironment. Additionally, Notch is pivotal in tumor development
and plays a dual role acting as both oncogene and tumor suppressor. In this review, we summarize the
role of the Notch pathway in HNSCC, with a special focus on its compelling role in major events of tumor
initiation and growth.
DOI: https://doi.org/10.3390/ijms20061520
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-179702
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Porcheri, Cristina; Meisel, Christian Thomas; Mitsiadis, Thimios (2019). Multifactorial Contribution
of Notch Signaling in Head and Neck Squamous Cell Carcinoma. International Journal of Molecular
Sciences, 20(6):1520.
DOI: https://doi.org/10.3390/ijms20061520
 International Journal of 
Molecular Sciences
Review
Multifactorial Contribution of Notch Signaling in
Head and Neck Squamous Cell Carcinoma
Cristina Porcheri † , Christian Thomas Meisel † and Thimios Mitsiadis *
University of Zurich, Institute of Oral Biology, Plattenstrasse 11, CH-8032 Zurich, Switzerland;
cristina.porcheri@zzm.uzh.ch (C.P.); christian.meisel@zzm.uzh.ch (C.T.M.)
* Correspondence: thimios.mitsiadis@zzm.uzh.ch
† These authors contributed equally to this work.
Received: 28 February 2019; Accepted: 22 March 2019; Published: 26 March 2019


Abstract: Head and neck squamous cell carcinoma (HNSCC) defines a group of solid tumors
originating from the mucosa of the upper aerodigestive tract, pharynx, larynx, mouth, and nasal cavity.
It has a metastatic evolution and poor prognosis and is the sixth most common cancer in the world,
with 600,000 new cases reported every year. HNSCC heterogeneity and complexity is reflected in a
multistep progression, involving crosstalk between several molecular pathways. The Notch pathway
is associated with major events supporting cancerogenic evolution: cell proliferation, self-renewal,
angiogenesis, and preservation of a pro-oncogenic microenvironment. Additionally, Notch is pivotal
in tumor development and plays a dual role acting as both oncogene and tumor suppressor. In this
review, we summarize the role of the Notch pathway in HNSCC, with a special focus on its compelling
role in major events of tumor initiation and growth.
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1. Introduction
1.1. Developmental Stages of Oral Squamous Carcinoma
Solid tumors are abnormal cellular masses that originate from a cohort of cells within the
tissue, disrupting its structure and organization. In dependence of the tissue of origin, solid tumors
are classified into either sarcomas or carcinomas. Sarcomas originate from transformed cells of
mesenchymal origin in the bone or the soft tissues (e.g., cartilage, muscles, vascular tissue, or connective
tissue). Carcinomas arise from epithelial cells that line the wall of a variety of organs, such as the skin,
the lungs, the digestive system, and the oral cavity. The most common types of carcinoma are basal
cell carcinoma and squamous cell carcinoma. While basal cell carcinoma is the most common cancer
of the skin, squamous cell carcinoma is the most common in head and neck cancer, accounting for
approximately 90% of cases [1].
Head and Neck Squamous Cell Carcinoma (HNSCC) encompasses all tissues of the oral cavity.
This cancer is often highly aggressive, especially in young patients under 40 years of age, and with a
poor prognosis if diagnosed in advanced stages (III–IV), due to metastasis [2–4].
Histologically, the carcinogenesis is divided into three progressive stages: hyperplasia, atypical
hyperplasia (dysplasia), and invasive cancer (Figure 1).
Hyperproliferation leads to an increase in cell numbers of the epithelium (hyperplasia), without
a change in shape. If cell division becomes deregulated, cells become abnormal in shape and lose
classical morphological features, a stage called dysplasia. As a result, the tissue has a disordered
appearance and changes in cell morphology can be observed. However, dysplasia is not a guarantee
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that cells have acquired a cancerous stage, though possible genetic alterations have occurred leading
to a predisposition of cancer.
In a higher grade of dysplasia, the carcinoma in situ, epithelial cells remain within their tissue
without spreading into adjacent structures. At advanced stages, dysplastic cells breach the basement
membrane and invade nearby tissues and organs, forming metastases (Figure 1).
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cells change morphology but remain locally confined in the epithelial layer. Hyperkeratosis is 
detectable in the most external epithelial layer. (D) Cancer cells breach the basement membrane, 
invading the underlying mesenchyme and neighboring tissues. Invasive cancer cells enter the blood 
stream and establish new secondary tumors (metastases) in distant organs. 
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Intraorally, 40–50% of oral cancers commonly affect the tongue [6]. The lingual epithelial tissue is 
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consists of four tightly packed layers, with a varying degree of differentiation. The basement 
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compartment. Cells of the basal layer are relatively round in shape and proliferative. The ratio of 
nuclear versus cytoplasmic size is reduced the further the cells differentiate and migrate toward the 
outer layer, while they additionally flatten out and become squamous in shape. Above the 
submucosa, which contains blood vessels, minor salivary glands, nerves, structural fibers, fibroblasts, 
and other cell types, lies the stratum basale (basal layer) (Figure 1 and Figure 2A). It consists of a layer 
of cuboidal cells and it is thought to harbor the undifferentiated cells of the tongue epithelium. These 
cells have organelles which are typical for protein-producing cells and express intermediate filaments 
of cytokeratin 5 and 14, respectively. Basal cells divide continuously and differentiate toward the 
outer layers. The stratum spinosum (prickle layer) contains cells that are characteristically bigger in 
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blood vessels, minor salivary glands, nerves, structural fibers, fibroblasts, and other cell types, lies
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and 2A). The granular layer is characteristically built-up by flattened cells and contains the basophilic
keratohyalin granules and densely packed keratin filaments. The outmost layer is the stratum corneum,
consisting of a pure keratinized layer. These cells have no organelles and no more nuclei are present
(orthokeratinized) (Figures 1 and 2A). In HNSCC, the epithelial layer is thought to be the affected
tissue, leading to cancer formation. In the early stage of oral cancer, cells undergo hyperproliferation,
increasing their number in the lower third of the epithelium, but display a normal differentiation
program [7]. In advanced cancer stages, squamous cells become dysplastic, i.e., highly proliferative and
morphologically abnormal, starting to infiltrate different layers of the epithelium [8] (Figures 1 and 2A).
Ultimately, these cells degrade the subepithelial basement membrane and invade the underlying tissue
structure, thus acquiring the ability to invade distant tissues and form metastases (Figure 1).
Salivary gland tumors account for up to 6.5% of all head and neck cancers [9]. The salivary glands
comprise the parotid, submandibular, and sublingual glands, together with minor glands scattered
over the labial, buccal, palatal, and lingual surfaces of the mouth cavity [10]. Tumors can originate in
either the major or the minor salivary glands, but approximately 80% of them arise in the parotid gland,
15% in the submandibular gland, and 5% in the sublingual and minor glands (2005 World Health
Organization (WHO) classification of epithelial salivary gland tumors). Salivary glands are divided
into lobules by connective tissue septa engulfing the functional portion of secretory units (acini) and
ducts. Acini can be serous, if they secrete proteins dissolved in isotonic water fluid; mucous, if they
secrete the lubricant mucous or mixed, histologically distinguishable for their demilune structure,
where serous acini surround mucous acini [11]. The secretory units abut onto the intercalated ducts,
limited by a row of cuboidal epithelium and myoepithelial cells underneath. These ducts continue as
striated ducts, with a basement membrane to allow water reabsorption and ion secretion. The striated
ducts end into interlobular ducts, enclosed by columnar epithelium [10]. More than 95% of salivary
gland tumors are of epithelial origin, with the most malignant form being represented by the basal cell
adenocarcinoma, mucoepidermoid carcinoma, adenoid cystic carcinoma, and squamous cell carcinoma.
Due to the limited molecular understanding of the salivary gland tumors, the majority of patients
undergo a surgical removal of the primary tumor followed by radiotherapy. Surgical intervention
has severe limitations in efficiency, and recurrence occurs in 40–45% of cases as a consequence of
incomplete resection. Additionally, the invasive nature of the procedure often leads to serious side
effects, such as debilitating facial disfigurement. Surgery is normally accompanied by radiotherapy,
that directly affects salivary glands functionality, leading to dryness, increased risk of oral infections,
problems in mastication, and impaired language skills [12–14].
HNSCC encompasses many site-specific oropharyngeal cancers [15]. Typical risk factors for these
oral epithelial cancers can be subdivided into three groups: chronic irritants of the aerodigestive tract
(e.g., tobacco and alcoholic beverages), genetic syndromes caused by genomic instability and DNA
repair defects, and human papillomavirus infections leading to cell cycle alterations. Patients with
a history of tobacco consumption have more gene mutations associated with tumor growth than
non-tobacco users, especially when combined with the abuse of alcohol [16]. Additionally, a diet
low in fruits and vegetables has been connected to favor the development of oral squamous cell
carcinoma [14,16–18].
The most conventional methods of treatment are limited to surgical removal of the primary tumor,
radiation, and chemotherapy. Treatment of early HNSCC usually involves either radiation or surgery,
with a favorable prognosis [19].
However, currently the 5-year overall survival rate after conventional treatment is approximately
at 40–50%, due to high incidence of treatment resistance, consequent recurrence of the tumor, and
following lymph node metastasis [20].
Therefore, to develop efficient and ultimate treatment therapies, it is paramount to identify
cellular and molecular mechanisms of HNSCC tumor formation, progression, treatment resistance
and metastasis. Normal epithelial cells might develop into cancerous cells as a consequence of specific
genetic alterations, gene deletions/amplifications or epigenetic modifications. Often these genes are
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key players in regulating cell cycle and proliferation such as the Notch, Wingless/Integrated (Wnt),
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), p53, or mitogen-activated
protein kinase (MAPK) pathways.
1.2. The Notch Pathway in Oral Physiology
The Notch pathway is an evolutionary well conserved pathway involved in cell-to-cell
communication [21]. It is required for cell fate decisions at multiple stages of embryonic development
as well as in the adult organism, while dysregulation of the pathway is associated with genetic and
acquired diseases, including cancer.
The activation of the Notch pathway is initiated when a membrane-bound Notch receptor interacts
with a specific ligand on the adjacent cell, therefore regulating intercellular signaling. In mammals,
four Notch receptors have been described (Notch1, Notch2, Notch3, and Notch4) and five ligands: two
of the Jagged family (Jagged 1 and Jagged2) and three members of the Delta-like family (Dll1, Dll3,
Dll4). The canonical Notch signaling pathway is initiated by the interaction between ligand and Notch
receptor on a juxtaposed cell in trans. Upon ligand association, the ligand is endocytosed, leading
to a pulling force on the Notch Extracellular Domain (NECD) of the receptor. As a result, the three
cysteine-rich Lin-12/Notch Repeats (LNR) are exposing the S2 cleavage site on the receptor [21–23].
The S2 cleavage site is proteolytically processed by A Disintegrin And Metalloproteinase 10/17
(ADAM10/ADAM17) [22]. Upon S2 cleavage, the membrane-tethered Notch extracellular truncation
(NEXT) is formed. NEXT harbors the substrate for the γ-secretase complex. The γ-secretase complex
cleaves NEXT within the transmembrane domain at the S3 cleavage site. This creates a Notch
intracellular domain (NICD). Upon S3 cleavage, the NICD binds to importin α3, α4, or α7 [24]
with its nuclear localizing sequence (NLS). In the canonical model, NICD interacts with recombining
binding protein suppressor of hairless (RBPj) (alternatively known as: CSL, C promoter-binding
factor 1 (CBF1)/Suppressor of Hairless/Lag-1), and translocates into the nucleus to regulate the
transcription of specific Notch-target genes (such as Hairy And Enhancer Of Split 1 (HES)1, HES5,
Hairy/enhancer-of-split related with YRPW motif 1 (HEY)). In the noncanonical activation of the
pathway, Notch cleavage is also induced by ligand–receptor interaction on the surface, but pathway
transduction works independently from RBPj. Recently, noncanonical activation of Notch has been
associated with tumorigenic events in various cancers (breast cancer tumor progression, leukemia
and hematopoietic proliferation, neuroblastoma models) [25–30]. Post-translational modification of
the Notch receptors and ligands can influence their level of activation, which subsequently affects
downstream targets. One of these processes is glycosylation. The level of glycosylation of the Notch
receptor directly influences the affinity of the receptor for a specific ligand. A specialized family of
N-acetylglucosaminidyltransferases, the Fringe enzymes, initiate the elongation of the O-linked fucose
residues on the epidermal growth factor (EGF)-like repeats, preventing interaction of Notch with
Jagged ligands, but not Delta-like ligands. Initially identified in Drosophila, three homologues of
the Fringe proteins have been identified in mammals: Lunatic Fringe (Lfng), Maniac Fringe (Mnfg),
and Radical Fringe (Rfng) [31–33]. They play an essential role during embryonic development, as
demonstrated by somites malformation in the Lfng-mutant. Recently, their importance has been
associated with cancer development, where decreased levels of Lfng are a hallmark of triple-negative
breast cancer and Lfng blocked mammary stem cell proliferation [34]. In conclusion, the Notch pathway
can be regulated at various levels, besides the mere control of genetic expression. Its duration and
timing of activation might therefore largely vary due to the extracellular conditions to which the cell is
exposed. These factors highlight the importance of studying the pathway within its tissue context,
maintaining the complexity of the surrounding microenvironment.
In the oral cavity, members of the Notch pathway are mainly confined to the oral mucosa. The oral
mucosa represents the biggest organ of the oral cavity containing temperature and tactile receptors
and can be subdivided into three types: (i) The lining mucosa is the most represented in the oral
tissue covering 60% of the surface area, (ii) the masticatory mucosa (representing approximately
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25%), and (iii) the specialized mucosa (15% of the total oral mucosa) [35]. The lining mucosa is a
stratified squamous nonkeratinized epithelium supported by a more elastic and flexible connective
tissue. This mucosa type lines the surface of the lips, cheeks, floor of the mouth and covers the
ventral area of the tongue. The masticatory mucosa represents a keratinized epithelium and is tightly
attached to the underlying tissues by a collagenous connective tissue, or lamina propria. This mucosa
is designated to withstand abrasion due to mastication and covers tissues such as the gums and
the palate. The specialized mucosa lines the dorsal part of the tongue. It is a masticatory mucosa
by function, but additionally characterized by its high extensibility and lingual papillae. Notch1
expression is detectable throughout all mucosa types, although with varying degree of intensity within
the epithelial layers, i.e., higher expression is detectable in the stratum basale and spinosum, while it
is faintly expressed in the stratum granulosum and corneum [36–38]. Notch2 receptor is expressed
in the tongue squamous epithelium, [39,40], whereas Notch3 is expressed in the stratum basale and
spinosum [35,38,39] (Figure 2). The ligand Jagged1 was reported to be strongly expressed in the
epithelial layers stratum basale and spinosum, while a gradually fainting signal was detected in the
outer layers stratum granulosum and corneum [36,41]. Jagged2 expression was detected throughout
the epithelial layers of the tongue, resembling the expression pattern of Notch1. However, a strong
expression of Jagged2 limited to the stratum basale was also reported [35,38,39]. Throughout the
epithelial oral mucosa layers, only a low expression was reported for the ligand DLL4 [38,39] (Figure 2).
To support oral homeostasis and functionality, secretion from the salivary glands helps preserving
a healthy oral environment, and it is essential for mastication and speech.
The Notch signaling pathway is expressed in submandibular gland tissue, although its role has
not been fully characterized. Notch1-4 receptors are present in the normal salivary gland tissue, as
well as the ligands Jagged1, 2, and Delta1 (DLL1) [42]. Expression was found scattered in the ductal as
well as acinar cells of the tissue, of which the latter often displayed a nuclear staining.
In conclusion, components of the Notch signaling pathway are present in the major structures of
the oral cavity and potentially partake in their functionality.
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1.3. Notch in Oral Pathological Conditions
Mutations in the Notch pathway lead to a variety of disorders and malformations. Craniofacial
disorders, such as cleft lips and palate represent the most common developmental defects in humans,
and also depends on an aberrant reorganization of the epithelial layer during palate elevation and
fusion. The interaction Notch-Jagged has been directly associated with misregulated fusion, and
mutant mouse models for Jagged2 develop palate clefting [43,44].
Alagille syndrome is a genetic disorder characterized by a number of abnormalities, which
include ocular abnormalities, heart defects (pulmonic stenosis; ventricular septal defect), vertebral
malformations, characteristic facial features, and cholestasis. Based on genetic screenings, most cases
are thought to be caused by mutations in the Jagged1 and Notch2 genes [45].
In teeth, the Notch pathway plays a crucial role in the development of tooth germ and it is involved
in regeneration of injured tissue in the adult teeth. Notch is essential for odontoblasts differentiation,
mineralization of hard tissue, determination of the cusp architecture, and root formation. Upon carious
or traumatic injury, the Notch signaling is triggered in pulpal mesenchymal cells, suggesting a role of
the pathway in repair [42,46–50].
During vasculature establishment and maintenance, the altered expression of Notch3 and Notch4
receptors results in arteriovenous malformation. Sporadic lesions might occur that lead to increased blood
flow and high pressure, disrupting the integrity of vessels and exposing them to facilitated rupture [51].
In important muscular diseases, such as the Duchenne Muscular Dystrophy, the role of
Notch in maintenance of tissue homeostasis is linked with its involvement in stem cell-dependent
regeneration [52,53]. Oral muscles are progressively affected by the disease, and potential restoration
of their functionality might derive from the reduction in Jagged1 expression [54,55]. Finally, during
thyroid development, malformation can occur to generate ectopic portion of thyroid tissue located at
the base of the tongue. The structure takes the name of lingual thyroid and its origin is likely controlled
by the Notch signal normally regulating correct thyroid formation via the Jagged–Notch axis [43,56,57].
1.4. Notch Expression in Oral Squamous Cell Carcinoma
Expression of Notch1 is pivotal for early cancer development. Similarly to other carcinoma,
such as skin squamous cell carcinoma, the expression of Notch1 in the oral squamous epithelium
was localized in the basal cells, which was found to be significantly downregulated in oral epithelial
dysplasia [58]. Loss of Notch1 promotes a tumor-inducing effect, impairing barrier integrity and
generating a wound-like environment in the underlying stroma. These findings strongly suggest that
a reduction in Notch1 activity is a crucial event in oral cancer formation and progression. Based on
bioinformatic studies and evaluations of Oral Squamous Cell Carcinoma (OSCC) data sets, the receptor
Notch1 was the 4th highest protein of interest involved in oral cancer [59]. Inactivating mutations of
Notch1 can be found in approximately 10% of all cases of squamous cell carcinoma including the oral
cavity [60], indicating that Notch1 is one of the most mutated gene in squamous cell carcinoma. In line
with this data, Notch effectors Hes1 and Hey1 were overexpressed in 32% of HNSCC cases, but only
in absence of Notch1 inactivating mutation [61].
Numb is a membrane-associated protein which is expressed inversely to Notch. Numb is
able to function as a negative regulator of Notch by recruiting the ubiquitination machinery to the
plasma membrane, leading to Notch receptor ubiquitination and its subsequent degradation [62–64].
Overexpression of Numb was identified in OSCC samples, although these results are in contradiction to
previous findings in esophageal squamous cell carcinoma, where Numb transcripts were decreased [65].
Furthermore, in human OSCC cell lines the overexpression of Numb results in a decreased cell
proliferation, migration, and invasion, which was also detectable in esophageal squamous cell
carcinoma [65,66]. siRNA-treated cells in vitro, targeting Numb, resulted in increased cell growth as
well as invasion. However, the in vivo translation of the analyses was not conclusive [66].
Jagged1 and Jagged2 transcripts were significantly increased in OSCC cell lines as well as
patient samples in comparison to non-neoplastic tissue [36,67]. The ligand Jagged1 was shown to be
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upregulated in OSCC cell lines and tissue samples; interestingly the downregulation of Jagged1 in the
OSCC resulted in a decrease of cell proliferation in vitro as well as tumor growth in vivo, identifying
Jagged 1 and Jagged2 ligands as potential therapeutic targets [41,67].
The metalloprotease a disintegrin and metalloprotease domain 17 (ADAM17) is overexpressed in
a human OSCC cell line leading to an increase in cell viability and migration. Furthermore, after the
transplantation of ADAM17 overexpressing cells, an increase in tumor cell proliferation as well as in
tumor size could be detected [68]. In reverse, an inhibition of ADAM17 in HNSCC in vivo resulted in
decreased tumorigenesis.
1.5. Notch and the Influence on Vasculature
A hallmark of cancer is increased angiogenesis. This process involves branching and formation of
new blood vessels, required to guarantee optimal supply of nutrients for the tumor microenvironment.
During angiogenic sprouting, tip endothelial cells start to migrate and proliferate in response to
proangiogenic factors locally released. In contrast, neighboring stalk cells exposed to the same
stimuli are resistant to migration and proliferation, remaining attached to the original vessels.
The mechanism regulating endothelial sprouting is Notch-dependent in a variety of models (from
zebrafish to mammals [69–72]). Connector and patent endothelial cells express high Notch, resulting
in downregulation of the Vascular Endothelial Growth Factor (VEGF) transcript and its receptor
VEGFR2 (also known as Kdr), which in turn controls endothelial migration and proliferation rate [73].
Consistently, tip endothelial cells have high level of VEGF and express the Dll4 ligand, able to activate
Notch in the neighboring cell. On the other hand, interaction of the receptor with Jagged1 leads
to reduced sprouting, suggesting that the choice of the ligands determine the balance between tip
and stalk cells in arterial growth [74]. The Fringe glycosyltransferases, are central in this decision,
as the interaction Notch-Dll4 is preferred over Notch-Jagged1 upon glycosylation of the ligand [74].
Tumor vessels abide to similar mechanisms of growth, using the Notch signaling to regulate the
supply of blood borne factors. Pathological angiogenesis relies on local clues to recess or initiate
growth. When a tissue lacks oxygen, blood vessels branch up into the hypoxic tissue to contrast tissue
decay, and vasculature start to recess when vascular coverage allows sufficient perfusion. In contrast,
tumor microenvironment continuously supports angiogenesis, due to the release of local inflammatory
cytokines and angiogenic factors (Figure 3). Macrophages found in the tumor microenvironment
participate in the regulation of vasculature remodeling, and strongly express Notch1, Notch2, and
Notch4, together with VEGFR1 [75,76] (Figure 3). Additionally, tumor vasculature overexpresses
the Dll4 ligand, resulting in a hypersprouting phenotype [77]. In lung cancer, VEGF directly affects
expression of Dll4 in tumor vessels [78], as well as in neuroblastoma models, where blocking VEGFR2
increases the level of Jagged1 expression and consequent Notch1 hyperactivation [79]. Similarly
to other solid tumors, HNSCC relies on the local network of blood vessels to support its growth,
maintenance and metastatic invasion [80] (Figure 3). Particularly, the Notch ligand Jagged1 induces
endothelial activation of Notch in HNSCC, promoting local sprouting [81]. The Notch3 receptor
was reported to actively signal in stromal fibroblasts of OSCC human samples, inducing an increase
in tumor angiogenesis [82]. In a HNSCC heterotopic xenograft tumor model, treatment with the
epidermal growth factor receptor (EGFR) blocker Cetuximab inhibits angiogenesis by downregulating
Notch1 and Hypoxia-inducible factor 1 alpha (Hif1α) subunit [83]. Finally, blocking Notch in tumor
vasculature significantly reduces tumor growth, suggesting that endothelial Notch is a potential target
for disrupting tumor microenvironment and pathological progression.
Summarizing, Notch signaling has a pivotal influence on regulating angiogenesis in various
phases of oral tumor development, influencing its growth and formation of metastasis.
1.6. Notch and Epithelial-to-Mesenchymal Transition
Fate change is essential in tissue determination during embryonic development [84]. During
gastrulation and neural crest stem cells’ migration, cells of epithelial origin face dramatic morphological
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changes, downregulate anchoring molecules, and increase their motility. Epithelial cells can be converted
into fibroblast-like cells by changes in gene expression and cytoskeletal organization, in the process of
Epithelial-to-Mesenchymal Transition (EMT). Thus, they can leave the ectoderm to migrate through
the disrupted basal lamina underneath and form new distal organs. Once they have reached their
destination, the process can be reverted, and mesenchymal cells might convert back into epithelial
cells. Beside the process of organ formation during development, EMT occurs in repair processes,
such as wound healing [85]. Dysregulation of EMT can result in scar formation and fibrosis with
consequent malfunctioning of the organ [86]. Similarly, during metastases, cells change their structure
and behavior activating the EMT program. They can invade the adjacent underlying tissues and
form metastases [87]. At the molecular basis of EMT, dynamic remodeling in cadherin and integrin
expression reflects in structural, motility, and fate changes of epithelial cells [88]. Notably, integrin
β4, α5β1, and αVβ6 are among the first molecules being altered during metastasis, invasion, and
progression of carcinoma cells. Additionally, changes in the cadherins panel of expression result in
dramatic structural changes in epithelium, and specifically in the adherens junctions deprived of E-cadherin
expression [89,90]. Cadherin switching from E-cadherin to N-cadherin is common during tumorigenic
EMT, and correlates with increased migration, invasion, and poor prognosis in cancer. The transcription
factor Snail1 is a major regulator of E-cadherin expression, reducing cell-to-cell adhesion and
consequently causing destabilization of epithelial architecture and EMT. Notch1 overexpression leads
to increased levels of the transcription factor Snail homolog 1. The use of gamma-secretase inhibitors
N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (GSI DAPT) to inhibit Notch
signaling in carcinoma, leads to an attenuation of transforming growth factor-β (TGF-β), which in
turn controls Snail1 expression, indicating a role of Notch in EMT during cancer progression [91]. In a
similar manner, the expression of receptors Notch2 and Notch3 correlates with Snail1 expression in
cancer samples from patients with carcinoma of unknown primary (CUP syndrome) [92].
In a subset of lung cancer cells, Gefitinib-resistant cells displayed an EMT phenotype as well as
an increase in Notch1 expression, when compared to their parental cells. On the other hand, when
Notch1 was ablated in parental lung carcinoma cells, EMT was inhibited [93]. Gefitinib-sensitive
parental cells were capable of acquiring an EMT phenotype upon Notch1 overexpression, which
leads to the conclusion that Notch1 is a key player in the regulation of EMT [93]. In OSCC, it was
shown that the expression of Notch receptors, ligands as well as Snail1 and other classical targets of
Notch, are increased in hypoxic conditions. Hypoxia also decreased the expression of E-cadherin,
leading to an increased motility of OSCC cell lines, an effect that could be stopped by inhibiting Notch
signaling using GSI DAPT. This suggests that Notch might regulate EMT in OSCC cell lines under
hypoxic conditions [94]. Cadherin switching was found in 30 of 80 HNSCC cases and correlates with
histological changes, and lymph nodes metastasis [95]. Downregulation of E-cadherin has been found
in OSCC cell lines, together with up-regulation of vimentin, a marker of mesenchymal phenotype [95].
Particularly, vimentin expression was localized in the cytoplasm of OSCC cells, directly at the invasive
tumor front [95]. Taken together, these observations point at the Notch pathway as major regulator of
EMT in a variety of cancerogenic conditions (Figure 3).
1.7. Notch and Cancer Stem Cells
Notch is crucial in stem cell maintenance and tissue regeneration processes [96]. Furthermore,
a role for Notch in cancer stem cells have been hypothesized in the last years [97]. Investigations in
breast cancer, glioma, pancreatic, prostate and hepatocellular carcinomas, have been linked to Notch
and provided an insight to its direct influence on the maintenance of cancer stem cell (CSC) within
the tumor [98–104]. CSC are able to self-renew and therefore take part in the regeneration of the
tissue. A protective microenvironment preserves this ability, sustaining different signaling pathways,
molecular circuits and epigenetic modifications.
A typical feature of the cancer stem cell phenotype is the resistance to antitumor treatments, such
as radiation or chemotherapy, leading to a high incidence of reoccurrence of cancer in patients [97].
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In breast cancer, Notch was found increased in stem cells derived mammospheres, suggesting an
activation of the pathway in the subpopulation of self-renewing, undifferentiated progenitors [105].
Additionally, the use of GSI DAPT gamma-secretase inhibitor, strongly hampered sphere formation as
well as their proliferation ability. Using a Her2/Neu positive xenograft model treated with GSI DAPT
and Herceptin (a monoclonal antibody used in combination with chemotherapy), blocked cancer
growth when compared with treatments with Herceptin alone and additionally prevent reoccurrence
of the tumor [106]. Therefore, the use of GSI DAPT on some solid tumors indicates that Notch has a
pivotal role in the maintenance of cancer stem cell-like cells.
Cancer stem cells have been identified in oral squamous cell carcinoma. Tumors generated from
CD44-cancer stem cells sorted cells showed increased expression of β-catenin, E-cadherin, and low
levels of Bmi1, Snail1, and Slug, all markers for increased tumorigenicity [107]. On the other hand, the
usage of CD44 as CSC marker remains controversial, with some work demonstrating its expression in
more differentiated cells [108]. Markers for undifferentiated progenitors can also be found in OSCC,
such as octamer-binding transcription factor 4 (OCT4), NANOG, and sex determining region Y-box 2
(SOX2) [109,110] in association with oncogenes such as signal transducer and activator of transcription
3 (STAT3) (promoting pro-oncogenic inflammation) [111], CD24 (with angiogenic potential) [112],
CD133, and Musashi1 (classically associated with undifferentiated, stem cell phenotype) [113,114].
In OSCC, the prolonged inflammatory microenvironment exposes CSCs to a continuous high level of
tumor necrosis factor alpha (TNF-α), enhancing expression of genes for stem cells, chemo-resistance
and the ability to produce tumoroids. In this context, Notch1 plays a coordinating role, as inhibition of
the Notch-Hes1 signaling inhibits CSC phenotype in OSCC [115] (Figure 3).
1.8. The Dual Role of Notch as an Oncogene and a Tumor-Suppressor
The role of the Notch pathway in solid tumors remains controversial, as it has been associated
with both tumorigenic and tumor-suppressive roles [116].
The neoplastic role of Notch was first discovered in patients suffering from human T cell acute
lymphoblastic leukemia (T-ALL). In more than 50% of T-ALL cases, the patients have a chromosomal
translocation (q34; q34.3) resulting in a truncated Notch receptor, which leads to a constantly active
Notch1. Over the years, studies on the role of Notch in regulating the immune system unraveled its
implication in inflammation and immune cell differentiation. The possibility to regulate the immune
system is of great importance in tumorigenesis, as extrinsic and intrinsic inflammation leads to favorable
conditions for tumor development. Notch functions in innate as well as adaptive immunity, by controlling
the differentiation of dendritic cells (DCs), natural killer cells (NKs), and T cells (Th1, Th2, and Tregs).
In physiological conditions, Notch is essential for T cell lineage commitment, where it acts as a checkpoint
to guarantee T cell lineage differentiation by preventing the commitment to other lineages such as myeloid
cells, DCs, and B cells [117,118]. Notch1 orchestrates the early phase of T-cell differentiation via DLL4 in
the thymus, which requires a downregulation of expression for a full T-cell differentiation [119].
Opposing roles of Notch in regard to the control of cell fate decisions were reported for two kinds
of NK cells at different maturation stages. Notch coordinates the differentiation of conventional NK
cells, while the innate lymphoid cell (ILC)-derived natural cytotoxicity receptor (NCR) NKp44+ group
(NCR+ILC3) remains suppressed in its differentiation [120].
Transient activity of Notch mediates myeloid differentiation by increasing mRNA levels of
myeloid specific transcription factor PU.1 [121]. Notch ligands DLL and Jagged might lead to opposite
effects on myeloid cells: DLL1-expressing fibroblasts promote DC differentiation and activation of
Notch, while Jagged1 promotes immature myeloid cells [122]. It was reported that some signaling
molecules involved in tumor-promotion, are modulated by the cells of the immune system, and might
directly regulate the Notch pathway. High expression of Notch1, 2, and Jagged1 can be correlated with
tumor progression of myeloma and it was proposed that Notch has an activating role of interleukin
6 (IL-6) proliferating signals in the bone marrow, enhancing tumor growth [123]. The cross-talk of
TNF-α, Notch and inhibitor of nuclear factor kappa-B kinase subunit kinase β (Ikk2) (component of
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nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) signaling pathway) leads to a
suppression of the nuclear receptor Pparg, in an animal model of pancreatic cancer. Under normal
conditions, Pparg encodes anti-inflammatory receptor Pparg. Hes1, a downstream target of the
Notch pathway, inhibits Pparg which subsequently hampers the autocrine inflammatory activity
of pancreatic tumor cells. As a result, production of inflammatory mediators (such as IL-6, IL-1β,
and TNF-α) was enhanced, supporting inflammation and cancer progression via Notch pathway
activation [124]. In OSCC cancer stem cells, NF-kB expression is specifically upregulated in both
OSCC biopsies and orospheres self-renewal assays [125] (Figures 3 and 4). In tongue squamous cell
carcinomas, IL-1β upregulates CXC chemokine receptor 4 (CXCR4), leading to cancer growth and
metastasis. This effect could be reversed by pharmacological interference of Notch1 signaling [126].
In conclusion, pro-inflammatory molecules such as IL-6, IL-8, and TNF-α can lead to Notch signaling
activation, enhancing tumor-promoting effects on epithelial cells.
In several solid tumors, including OSCC, the tumor microenvironment plays an essential role in
sustaining, nourishing, and protecting the cancerogenic core. The Notch signaling is implicated in the
maintenance of the tumorigenic microenvironment from various fronts. The tumor stroma develops in
parallel with the tumor epithelia, and it is involved in each step of cancer onset, development, and
progression. This cooperation between epithelium and underlying mesenchyme often remains ignored,
as many pharmacological treatments only target epithelium, neglecting the highly influential cancer
stroma. The cancer-associated fibroblasts (CAFs), build the majority of the cancer stroma in a number
of different cancers. CAFs directly influence the tumor microenvironment, secreting chemokines,
cytokines, and growth factors, and play a role in the degradation of the extracellular matrix [127].
These critical features make CAFs a strong protumorigenic factor. Recent studies report that CAFs are
capable of secreting a significantly higher amount of diffusible H2O2 than normal fibroblast, thereby
acting as a field effect carcinogen [128,129]. This leads to a protumorigenic stromal environment, by
increasing inflammatory and mitogenic factors, favoring primary epithelial cell transformation, and
increasing cancer cell aggressiveness [129]. Elevated levels of the Notch1 receptor have been found
during CAF activation, as shown in melanoma, where Notch1-expression negatively influences cancer
growth and invasion. On the other hand, the absence of Notch1 signaling in CAF leads to an increase
in melanoma invasion [130].
CAFs also play an important role in oral cancer, where they frequently exhibit an expression of
α-smooth muscle actin (α-SMA). It was shown that an upregulation of integrin-α6 in combination
with α-SMA, correlates with a poor prognosis for patients [131,132] and that CAFs expressing α-SMA
were shown to be involved in lymph node metastasis in oral squamous cell carcinoma [133,134].
As previously mentioned, the secretion of chemokines, cytokines, and growth factors by CAFs
promotes the degradation of the extracellular matrix through release of matrix metalloproteinase
(MPP), which is increased in HNSCC (Figure 3). Additionally, it was shown that the secretion of
hepatocyte growth factor (HGF) by CAFs leads to an increase in VEGF and IL-8, hence an increase in
angiogenesis. It also drives cell proliferation, migration, and invasion in HNSCC [135,136].
Summarizing, these factors emphasize the importance of the tumor microenvironment and
especially the role of CAFs in oral cancer progression.
In regard to tumor-suppressing roles, it could be shown that blockage of NF-kB, as well as
Ras, leads to invasive epidermal neoplasia mediated by the activity of tumor necrosis factor/c-Jun
N-terminal kinase (TNF/JNK) [137]. As NF-kB activation is triggered by Notch signaling, it raises the
question if Notch functions as a tumor suppressor via NF-kB activation in keratinocytes.
In a model of Notch1-deficient mice, basal cell carcinoma-like tumors arise spontaneously and
were associated with the activation of sonic hedgehog (Shh) signaling. Additionally, an increase
in β-catenin expression in the epidermis could be observed and reverted by active Notch1 [138].
These findings are supported by reports of reduced expression of Notch1, 2, and Jagged1 in basal cell
carcinomas of human samples [139]. In OSCC, the expression of the Notch1 gene is variably reduced,
as well as downstream target genes such as Hey1 [140]. In HNSCC cell lines, the overexpression of the
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active portion of Notch1 blocks cell cycle progression and produces a growth arrest. Similarly, in an
in vivo model for HNSCC, activation of Notch1 resulted in reduced tumorigenicity [141].
In conclusion, the functional consequences of Notch activation or inhibition strongly depend
on the tissue involved, the stage of cancer progression, and the single microenvironment features
embedding the tumor. Additionally, the variety of levels in which the Notch pathway activation can be
fine-tuned increases the complexity of the readout. A more detailed characterization of the conditions
in which Notch act as oncogene or tumor-suppressor is essential to develop efficient future approaches
for personalized medicine.
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1.9. Crosstalk between Notch and Other Major Pathways
The complex alterati n described in tumor development are often the result of multipathway
misregulation. Crosstalk of Notch and other molecular pathway is of central importance in aberrant
proliferation, apoptosis, and invasive phenotype.
The protein p53 is a pivotal tumor suppressor. It can be activated by diverse stress signals
to ultimat ly modulate cellular responses such as transient cell cycle arrest, senescence, and
apoptosis [142]. Crosstalk between p53 and the Notch pathway occurs at multiple levels. In an
animal model for T-ALL, p53 levels are reduced due to Notch1 activation. Notch1 activation leads
to an increased level of the E3 ubiquitin ligase mouse double minute homolog 2 (MDM2), which
targets p53 for subsequent degradation [143] (Figure 4). Furthe more, i vitro experiments using breast
cancer as well as keratinocyte cell lines show that activation of Notch causes an increased activity
of phosphoinositide 3-kinase v-Akt murine thymoma viral oncogene (PI3K-Akt) pathway (Figure 4).
This activation results in increased cell survival in response to MDM2 activity and subsequent reduction
of p53 protein [144, 45]. Aside of indirect up or downregulation of p53 by Notch activity, a direct
interaction of Notch and p53 has been proposed, leading to p53 inhibition of phosphorylation and its
DNA binding capability [146]. On the other hand, p53 activity increases upon induced expression of
the Notch downstream effectors HEY1 and HES1, which leads to reduced MDM2 expression [147].
Noteworthy, an increase in p53 expression has been correlated with Notch1-dependent apoptosis
and growth arrest in different tumor cell types, such as leukemia, hepatocellular cancer cells, and
oral tongue cancer cells [148–150]. Aberration in the EGFR-PI3K-AKT pathways is a hallmark for
oral cancer, where the cytoplasmatic phosphorylated form of AKT is expressed in more than 64% of
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cases [151–153] (Figure 4). In parallel, levels of expression of the receptor for EGF indicate a direct
correspondence with tumor size and stage. Blockage of AKT and PI3K phosphorylation induces cell
cycle arrest and apoptosis in OSCC cells [154]. During normal and malignant thymocytes development,
Notch and PI3K pathway crosstalk via Hes1 and the PI3K negative regulator phosphatase and tensin
homolog (PTEN). The downstream target Hes1 might directly downregulate expression of PTEN,
increasing PI3K activity [155] (Figure 4). In a screening for Notch1 inactivating mutation, the oncogenic
phenotype was associated with activation of the EGF-PI3K/AKT pathway and resulted in increased
cell proliferation, EMT, and invasion in OSCC cell lines [156].
Like the Notch signaling pathway, Wnt signaling is implicated in organ development and
regulation of stemness. Crosstalk between Wnt and Notch signaling has been reported in different
types of cancer [157,158]. In these settings, β-catenin/ T-cell factor/lymphoid enhancer factor (TCF)
causes an activation of the Notch signaling pathway and leads to expression of the downstream
oncogenes Myc proto-oncogene (Myc) [158], Hes1, cluster of differentiation 44 (CD44), nicotidamide
adenine dinucleotide phosphate oxidase 1 (Nox1), SOX9, ephrin type-B receptor 3 (EphHB3), and
Kruppel like factor 5 (KLF5) [157]. In OSCC, activation of the Wnt pathway can occur in absence
of β-catenin and colon-cancer specific mutations, suggesting that altered epigenetic changes might
compensate for the canonical activation of the pathway [159] (Figure 4).
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i fl
including cancer stem cell s lf-renewal, proliferation, angioge esis, and EMT. Wnt signali g
leads to β-catenin ac umulation, which subsequently leads o an activation of Notch signaling
and target gene transcription. Alternatively, aberrant Wnt sig aling bypasses β-catenin, ultimately
modulating Notch signaling. Inflammatory factors lead to an increase in NF-kB, which activates
PI3K-Akt signaling which in turn triggers p53 ubiquitination and degradation. The expression of
HES1 downregulates PTEN, leading to an increase in PI3K-Akt signaling, ultimately activating Notch
signaling. Dotted lines indicate Notch pathway regulation. Black arrows illustrate activation of the
pathway, T-arrows inhibition of the pathway.
During embryonic development, the Notch pathway regulates fate determination and cell number
in cooperation with the Hedgehog (HH) pathway. Mutations in HH-pathways have been found in
basal cell carcinoma, medulloblastoma, and rhabdomyosarcoma, and normally correlate with an
hyperactivation of the pathway. Recent studies on protein expression showed that SHH signaling
components are highly expressed in OSCC compared to normal tissue, with a restricted positive
pattern in epithelial cells [160–163].
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SHH has been shown to act on the target cells to increase the transcription of several genes,
including members of the Notch pathway. Additionally, the Notch pathway has been involved in the
regulation of intracellular localization of SHH, suggesting a critical bidirectional control of the two
pathways [164].
1.10. Current Animal Models for Oral Cancer
In the recent years, due to the development of new methods and techniques, several animal
models have been generated to study the initiation, formation and progression of HNSCC in vivo.
1.10.1. Chemically Induced Mouse Models of Oral Cancer
The chemical 4-nitroquinoline 1-oxide (4NQO) is a carcinogenic and mutagenic quinoline.
This chemical is used to generate an oral cancer model in mice and rats. 4-NQO is administered either
locally on the tongue or adding 4NQO to the drinking water [165–167]. Long-term administration of
4-NQO leads to a progression of carcinogenesis and includes hyperplasia, dysplasia, preneoplastic
as well as neoplastic lesions. The advantage of this model is to efficiently reproduce many
characteristic features of the human oral cancer development and progression. Molecular analyses
of pathways and testing novel therapeutic approaches can therefore be assessed at different stages
of the disease progression [3,4,167,168]. This model allows studies on tumor microenvironment
as well as vascularization, preserving the complex interaction of cell-to-cell communication and
cell-to-extracellular environment supporting tumor growth [168].
1.10.2. Transgenic Murine Models
The first developed genetic mouse model to study the development of oral-esophageal squamous
epithelium was generated exploiting the promoter of Epstein-Barr virus ED-L2 (L2). As the p53 gene
is mutated in 70% of HNSCC [169], this mouse was further crossed with p53+/− and p53−/− mice,
resulting in mice that develop invasive oral-esophageal squamous cell carcinoma. The final model
(L2D1/p53) enabled to study the roles of EGFR, p53, and CDK4 genes and their influence in the
formation of HNSCC [170]. The Tgfbr1/Pten 2cKO mice have an inducible control over the expression
of Tgfbr1/Pten genes [171,172]. Phosphatase and tension homolog (PTEN) is a tumor suppressor
gene and thought to play a key role in HNSCC. TGF-β signaling is known to have tumor-suppressing
as well as tumor-promoting roles in various cancers. Upon induced-ablation of the two genes, mice
develop hyperplasia in the oral epithelium [172]. The loss of Tgfbr1 and Pten was shown to lead to
cancer-related inflammation as well as cancer stem cell expansion in the basal epithelial layer of this
model [172]. Finally, a mutated form of Kirsten rat sarcoma viral oncogene homolog (K-Ras) was
expressed under the control of cytokeratin 5 and cytokeratin 14 (cK5 and cK14). The expression of
the two cytokeratin is confined to the stratified epithelia of the oral cavity, allowing a conditional
expression of the oncogene limited to the area of interest. Both mice models develop oral papilloma,
with some tissue specificity. Overexpression of KrasG12D under the control of cK5 affects the basal
epithelium, while under the regulation of cK14, alterations are mainly found in the basal layer of oral
mucosa and the tongue [173,174].
1.11. Therapeutic Strategies to Target Notch Signaling
As previously discussed, the cancer stem cells have the capability of self-renewal and amplify the
subset of undifferentiated progenitor cells. Notch is one of the key players in the maintenance of cancer
stem cells and it is involved in the regulation of motility and structural changes supporting metastasis.
Additionally, Notch plays a pivotal role in angiogenesis, critical for maintenance and progression
of tumorigenesis. Therefore, targeting Notch to eliminate cancer stem cells has become one of the
main pharmacological strategies to fight cancer [175]. On the other hand, Notch is essential for the
maintenance of homeostasis in a variety of tissues, and the development of agents with minimized
off-target side-effects requires a deeper understanding of the specific role of Notch in cancer. Two main
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strategies to target Notch signaling exist: (i) interference with Notch ligand–receptor interaction,
such as the use of monoclonal antibodies targeting specific regions for ligand–receptor binding or
(ii) preventing Notch receptor cleavages, inhibiting down-stream gene transcription (such as GSI
DAPT). Promising antitumor activity observations were made in experiments where GSI DAPT and
monoclonal antibodies (mAbs), were administered as a combined treatment. The antitumorigenic
effects could be detected in early stages of, e.g., lung cancer, sarcoma, colorectal cancer, thyroid
cancer [176]. Inhibiting Notch1 in an HNSCC xenograft mouse model resulted in reduced cancer stem
cell renewal. Furthermore, the combinatory use of chemotherapeutic drugs and Notch inhibitor caused
a reduction in the cancer stem cell population in vitro and in vivo. Another prominent target to inhibit
Notch signaling in cancer is the ligand DLL-4. Chemotherapy or radiotherapy in combination with
mAb against DLL-4 promoted tumor necrosis. This approach also reduced the frequency of tumor
initiating cells, impaired tumor angiogenesis, and delayed tumor relapse [78]. However, using mAbs
or GSI DAPTs causes severe side effects and requires periodic administration with lag phases for
patient recovery.
Additionally to chemotherapeutic agents, natural compounds and phytochemicals possess
useful anticancer properties that reduce cells proliferation, cancer stem cell renewal, and induce
apoptosis [177–179]. Alternative strategies of chemoprevention have been gaining increasing interest
during the last years due to their low toxicity and safeness over long term exposure. Specifically,
several natural compounds have been used to contrast various forms of carcinomas. Xanthohumol
(XN), derived from the humulus lupulus plant, and paeoniflorin (PF), from the Chinese peony, decrease
Notch signaling activation in a mouse model of breast cancer inducing apoptosis of tumorigenic cells
and suppressing proliferation [180,181]. Similarly, diallyl trisulfide (DATS), found in garlic, inhibits
the expression of ADAM10 and ADAM17 responsible for Notch signaling pathway activation in
transformed breast epithelial cells [182].
In small cell lung cancer (NSCLC) the flavone baicalein was found to reduce proliferation in vitro
as consequence of Notch1 and Hes1 downregulation of expression [183]. In both colon cancer
and melanoma, honokiol and withaferin A reduce Notch1, Jagged1, and Hes1 expression, inhibiting
carcinogenesis [184–186]. Curcumin is one of the most effective chemopreventive agents in oral cancer.
Curcumin is a polyphenolic derivate of turmeric from curcuma longa, and its anticancer activity has
been associated with the interference of the Notch-NF-κB-cyclinD1 axis. Curcumin downregulates
Notch1, which in turn inhibits NF-κB activation, resulting in a blockage of the downstream targets
VEGF and CyclinD1, involved respectively in tumor-angiogenesis and proliferation [187]. A similar
mechanism has been found in esophageal cancer cells and, more generally, might affect the formation
of cancer stem cells [177,188].
Summarizing, the inhibition of Notch signaling in malignant tumor enables a broad set of
approaches for future therapeutic strategies. Refining the spectrum of pharmacological targets is the
key factor to efficiently direct the treatment to the tumorigenic core.
2. Concluding Remarks
The Notch pathway is a well conserved molecular pathway essential for tissue homeostasis.
HNSCC is one of the most common solid tumors, in which the Notch pathway is altered; with
severe consequences for cellular proliferation and migration. Despite the urgent need for treatments
contrasting HNSCC, we are still lacking basic knowledge regarding the initiation and evolution of
the disease. As summarized in this review, the Notch pathway is involved in all major tumorigenic
events occurring during HNSCC development, including aberrant angiogenesis, regulation of stem
cell renewal, proliferation, and invasion. It therefore represents a central molecular element at the basis
of tumor formation and provides a promising therapeutic target for future HNSCC therapies.
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CAF Cancer-associated fibroblast
CBF1 C promoter-binding factor 1
CD44 Cluster of differentiation 44
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CXCR4 CXC chemokine receptor 4
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Hif1a Hypoxia-inducible factor 1 alpha subunit
HNSCC Head and neck squamous cell carcinoma
Ikk2 Inhibitor of nuclear factor kappa-B kinase subunit kinase β
IL Interleukin
ILC Innate lymphoid cell
JNK c-Jun N-terminal kinase
KLF5 Kruppel like factor 5
K-Ras Kirsten rat sarcoma viral oncogene homolog
Lfng Lunatic Fringe
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mAb Monoclonal antibody
MAPK Mitogen-activated protein kinase
MDM2 Mouse double minute homolog 2
MMP Matrix metalloproteinase
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Myc Myc proto-oncogene
NCR Natural cytotoxicity receptor
NECD Notch extracellular domain
NEXT Notch extracellular truncation
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
NICD Notch intracellular domain
NK Natural killer cells
NLS Nuclear localizing sequence
Nox1 Nicotidamide adenine dinucleotide phosphate oxidase 1
OCT4 Octamer-binding transcription factor 4
OSCC Oral Squamous Cell Carcinoma
PI3K-AKT Phosphoinositide 3-kinase v-Akt murine thymoma viral oncogene
Pparg Peroxisome proliferator-activated receptor gamma
PTEN Phosphatase and tensin homolog
RBPj Recombining binding protein suppressor of hairless
Rfng Radical Fringe
Shh Sonic hedgehog
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STAT3 Signal transducer and activator of transcription 3
SOX2 Sex determining region Y-box 2
TAM Tumor associated macrophages
TCF T-cell factor/lymphoid enhancer factor
T-ALL T cell acute lymphoblastic leukemia
TCF T-cell factor
TGF-β Transforming growth factor-β
Tgfbr1 Transforming growth factor-β receptor 1
TNF-α Tumor necrosis factor alpha
VEGF(R) Vascular endothelial growth factor (receptor)
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